146 related articles for article (PubMed ID: 15175539)
1. The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles.
Gilbert AR; Pinget C; Bovet P; Cornuz J; Shamlaye C; Paccaud F
Tob Control; 2004 Jun; 13(2):190-5. PubMed ID: 15175539
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison.
Cornuz J; Gilbert A; Pinget C; McDonald P; Slama K; Salto E; Paccaud F
Tob Control; 2006 Jun; 15(3):152-9. PubMed ID: 16728744
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of the first-line therapies for nicotine dependence.
Cornuz J; Pinget C; Gilbert A; Paccaud F
Eur J Clin Pharmacol; 2003 Jul; 59(3):201-6. PubMed ID: 12759795
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of clinical smoking cessation interventions in Thailand.
Tosanguan J; Chaiyakunapruk N
Addiction; 2016 Feb; 111(2):340-50. PubMed ID: 26360507
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research.
Cromwell J; Bartosch WJ; Fiore MC; Hasselblad V; Baker T
JAMA; 1997 Dec; 278(21):1759-66. PubMed ID: 9388153
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.
Feenstra TL; Hamberg-van Reenen HH; Hoogenveen RT; Rutten-van Mölken MP
Value Health; 2005; 8(3):178-90. PubMed ID: 15877590
[TBL] [Abstract][Full Text] [Related]
7. [Economic evaluation of pharmacotherapies for smoking cessation].
Antoñanzas F; Portillo F
Gac Sanit; 2003; 17(5):393-403. PubMed ID: 14599422
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.
Higashi H; Barendregt JJ
Addiction; 2012 Mar; 107(3):658-70. PubMed ID: 21883602
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
[TBL] [Abstract][Full Text] [Related]
10. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden.
Bolin K; Lindgren B; Willers S
Chest; 2006 Mar; 129(3):651-60. PubMed ID: 16537864
[TBL] [Abstract][Full Text] [Related]
11. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
Bertram MY; Lim SS; Wallace AL; Vos T
Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling.
Fiscella K; Franks P
JAMA; 1996 Apr; 275(16):1247-51. PubMed ID: 8601956
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience.
Croghan IT; Offord KP; Evans RW; Schmidt S; Gomez-Dahl LC; Schroeder DR; Patten CA; Hurt RD
Mayo Clin Proc; 1997 Oct; 72(10):917-24. PubMed ID: 9379693
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of a European primary-care physician training in smoking cessation counseling.
Pinget C; Martin E; Wasserfallen JB; Humair JP; Cornuz J
Eur J Cardiovasc Prev Rehabil; 2007 Jun; 14(3):451-5. PubMed ID: 17568248
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model.
Evans WK; Gauvreau CL; Flanagan WM; Memon S; Yong JHE; Goffin JR; Fitzgerald NR; Wolfson M; Miller AB
CMAJ Open; 2020; 8(3):E585-E592. PubMed ID: 32963023
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of a community based research project to help women quit smoking.
Secker-Walker RH; Holland RR; Lloyd CM; Pelkey D; Flynn BS
Tob Control; 2005 Feb; 14(1):37-42. PubMed ID: 15735298
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of the nicotine transdermal patch for smoking cessation.
Wasley MA; McNagny SE; Phillips VL; Ahluwalia JS
Prev Med; 1997; 26(2):264-70. PubMed ID: 9085397
[TBL] [Abstract][Full Text] [Related]
19. The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada.
von Wartburg M; Raymond V; Paradis PE
Int J Clin Pract; 2014 May; 68(5):639-46. PubMed ID: 24472120
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness analysis of smoking cessation interventions.
Shearer J; Shanahan M
Aust N Z J Public Health; 2006 Oct; 30(5):428-34. PubMed ID: 17073223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
